Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.47 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4607615 | 1.00 | KDM1A (0.47) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL28817269 | 1.00 | KDM1A (0.47) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL19297438 | 0.96 | KDM1A (0.47) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL19297536 | 0.96 | KDM1A (0.47) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL8724940 | 0.96 | KDM1A (0.47) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL21838934 | 0.87 | KDM1A (0.56) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL14804306 | 0.80 | KDM1A (0.56) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL26318046 | 0.80 | KDM1A (0.56) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL25341890 | 0.79 | SLC18A3 (0.49) | GRIA4HTR2CHTR2BAR | |
| SCHEMBL8326083 | 0.79 | KDM1A (0.47) | KDM1AHTR2CHTR2BHRH3AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108341774-B | Substituted quinolinone inhibitors | 首药控股(北京)股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2017-10-19 | — | — | US | disclosed |
| EP-1246797-B1 | CYCLOPENTYL SULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1390072-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6639107-B1 | Potentiating glutamate receptor function | ELI LILLY AND COMPANY | 2003-10-28 | — | — | US | disclosed |
| WO-2002089848-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
| EP-1246797-A1 | CYCLOPENTYL SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001042203-A1 | CYCLOPENTYL SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | KDM1A 1930/4885MAOB 1814/4885KCNH2 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.